Reozalimab

Modify Date: 2024-01-10 18:41:34

Use of Reozalimab

Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research[1][2].

Name	Reozalimab

Description	Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1
References	[1]. Pattabiraman, et al. Synthetic IL-7 and IL-7-anti-PD-1 antibody immunocytokines for cancer therapy. World Intellectual Property Organization, WO2023281484 A1 2023-01-12. [2]. Reozalimab. IMGT/mAb-DB.

Description

Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research[1][2].

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1

References

No Any Chemical & Physical Properties

Dichloromethane
CAS#:75-09-2

Polyacrylic acid
CAS#:9003-01-4

sodium carbonate
CAS#:497-19-8

Silicon dioxide
CAS#:7631-86-9

Triethanolamine
CAS#:102-71-6

Demeton
CAS#:126-75-0

Water
CAS#:7732-18-5

Diclofenac sodium
CAS#:15307-79-6

Budesonide
CAS#:51372-29-3